ArticleCancers2026
Real-World Outcomes of Palbociclib with Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: A Retrospective Study from Saudi Arabia.
Abdalrhman H Alanizi, Sarah N Al-Shaiban, Reema Alotaibi, Reem Qubaiban, Esra'a Khader, Ahmed S Alanazi, Hatoon Bakhribah, Nawal Alsubaie, Amani S Alrossies, Sireen Abdul Rahim Shilbayeh and 1 more
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Abdalrhman H AlaniziPharmaceutical Care Services, King Abdullah bin Abdulaziz University Hospital, Riyadh 11671, Saudi Arabia.ORCID 0000-0002-0754-7493 Sarah N Al-ShaibanDepartment of Pharmacy, Al Kharj Military Industries Corporation Hospital, Al-Kharj 16417, Saudi Arabia.ORCID 0009-0009-7559-9082 Reema AlotaibiPharmaceutical Care Services, King Abdullah bin Abdulaziz University Hospital, Riyadh 11671, Saudi Arabia.ORCID 0009-0005-2324-1565 Reem QubaibanNational Cancer Center, Riyadh 13315, Saudi Arabia.
Esra'a KhaderCollege of Pharmacy, Department of Pharmacy Practice and Science, University of Iowa, Iowa City, IA 52242, USA.
Ahmed S AlanaziClinical Pharmacy, Pharmacy Service Administration, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Hatoon BakhribahComprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Nawal AlsubaieDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
Amani S AlrossiesDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.ORCID 0009-0009-5358-0305 Sireen Abdul Rahim ShilbayehDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
Ammena Y BinsalehDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.ORCID 0009-0007-7174-3839 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
CDK 4/6 inhibitorsHER2-negativeHR-positivemetastatic breast cancerpalbociclibreal-world dataSaudi Arabia
Identifiers
PMID42073594
PMCPMC13115174
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390